Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Omeros (NASDAQ:OMERFree Report) from a hold rating to a sell rating in a research note released on Tuesday morning.

Omeros Stock Up 0.6 %

OMER opened at $3.46 on Tuesday. The company has a market cap of $217.53 million, a PE ratio of 10.81 and a beta of 1.38. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 10.80. Omeros has a twelve month low of $0.92 and a twelve month high of $7.80. The company has a 50-day moving average price of $3.91 and a 200 day moving average price of $2.96.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently made changes to their positions in OMER. First Trust Advisors LP raised its stake in Omeros by 2.4% during the 4th quarter. First Trust Advisors LP now owns 172,755 shares of the biopharmaceutical company’s stock worth $565,000 after acquiring an additional 4,130 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Omeros by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 312,409 shares of the biopharmaceutical company’s stock valued at $706,000 after acquiring an additional 4,170 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Omeros in the second quarter valued at about $27,000. Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 199.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 5,378 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Omeros by 3.0% in the first quarter. Bank of New York Mellon Corp now owns 205,160 shares of the biopharmaceutical company’s stock valued at $1,233,000 after acquiring an additional 5,938 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Read More

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.